The pharmacological management of NAFLD in children and adolescents

References

• Crespo M, Lappe S, Feldstein AE, et al. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. Metabolism. 2016;65:1161–1171.
   PubMed Web of Science ®Google Scholar
• Anderson EL, Howe LD, Jones HE, et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One. 2015;10:e0140908.
   PubMed Web of Science ®Google Scholar
• Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis [Internet]. 2010;28:155–161.
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009;58:1538–1544.
   PubMed Web of Science ®Google Scholar
• Loomba R, Sirlin CB, Schwimmer JB, et al. Advances in pediatric nonalcoholic fatty liver disease. Hepatology. 2009;50:1282–1293.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American gastroenterological association, American association for the study of liver diseases, and American college of gastroenterology. Gastroenterology. 2012;142:1592–1609.
   PubMed Web of Science ®Google Scholar
• Oddy WH, Herbison CE, Jacoby P, et al. The Western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. Am J Gastroenterol. 2013;108:778–785.
   PubMed Web of Science ®Google Scholar
• Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195–203.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20:15539–15548.
   PubMed Web of Science ®Google Scholar
• Caldwell S, Ikura Y, Dias D, et al. Hepatocellular ballooning in NASH. J Hepatol. 2010;53:719–723.
   PubMed Web of Science ®Google Scholar
• Alkhouri N, Hanouneh IA, Zein NN, et al. Liver transplantation for nonalcoholic steatohepatitis in young patients. Transpl Int. 2016;29:418–424.
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42:641–649.
   PubMed Web of Science ®Google Scholar
• Carter-Kent C, Yerian LM, Brunt EM, et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology. 2009;50:1113–1120.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Inui A, Fujisawa T, et al. Histopathological characteristics of non-alcoholic fatty liver disease in children: comparison with adult cases. Hepatol Res. 2011;41:1066–1074.
   PubMed Web of Science ®Google Scholar
• Nobili V, Marcellini M, Devito R, et al. NAFLD in children: A prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006;44:458–465.
   PubMed Web of Science ®Google Scholar
• Patton HM, Lavine JE, Van Natta ML, et al. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology. 2008;135(6):1961–1971.
   PubMed Web of Science ®Google Scholar
• Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:936–944.
   PubMed Web of Science ®Google Scholar
• Lonardo A, Ballestri S, Marchesini G, et al. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis. 2015;47:181–190.
   PubMedGoogle Scholar
• Rosso C, Mezzabotta L, Gaggini M, et al. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology. 2016;63:107–116.
   PubMed Web of Science ®Google Scholar
• Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017;46:85–95.
   PubMed Web of Science ®Google Scholar
• Fan J-G, Kim S-U, Wong VW-S. New Trends on Obesity and NAFLD in Asia. J Hepatol. 2017. [Epub ahead of print]. DOI:10.1016/j.jhep.2017.06.003
   Web of Science ®Google Scholar
• Fracanzani AL, Petta S, Lombardi R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol. 2017. [Epub ahead of print]. DOI:10.1016/j.cgh.2017.04.045
   PubMed Web of Science ®Google Scholar
• Wattacheril J, Sanyal AJ. Lean NAFLD: an underrecognized outlier. Curr Hepatol Reports. 2016;15:134–139.
   PubMedGoogle Scholar
• Seto W-K, Yuen M-F. Nonalcoholic fatty liver disease in Asia: emerging perspectives. J Gastroenterol. 2017;52:164–174.
   PubMed Web of Science ®Google Scholar
• Kim D, Kim WR. Nonobese fatty liver disease. Clin Gastroenterol Hepatol. 2017;15:474–485.
   PubMed Web of Science ®Google Scholar
• Feldman A, Eder SK, Felder TK, et al. Clinical and metabolic characterization of lean caucasian subjects with non-alcoholic fatty liver. Am J Gastroenterol. 2017;112:102–110.
   PubMed Web of Science ®Google Scholar
• Stefan N, Fritsche A, Schick F, et al. Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabetes Endocrinol. 2016;4:789–798.
   PubMed Web of Science ®Google Scholar
• Honda Y, Yoneda M, Kessoku T, et al. Characteristics of non-obese non-alcoholic fatty liver disease: effect of genetic and environmental factors. Hepatol Res. 2016;46:1011–1018.
   PubMed Web of Science ®Google Scholar
• Ballestri S, Nascimbeni F, Romagnoli D, et al. The role of nuclear receptors in the pathophysiology, natural course, and drug treatment of NAFLD in humans. Adv Ther. 2016;33:291–319.
   PubMed Web of Science ®Google Scholar
• Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. Dig Liver Dis. 2017;49:471–483.
   PubMedGoogle Scholar
• Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557–1565.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–97.e10.
   PubMed Web of Science ®Google Scholar
• Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65:589–600.
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836–1846.
   PubMed Web of Science ®Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038–1048.
   PubMed Web of Science ®Google Scholar
• Day CP, Of J. Steatohepatitis: a tale of two ‘hits’? Gastroenterology. 1998;114(4):842–845.
   PubMed Web of Science ®Google Scholar
• Ibrahim MA, Kelleni M, Geddawy A. Nonalcoholic fatty liver disease: current and potential therapies. Life Sci. 2013;92:114–118.
   PubMed Web of Science ®Google Scholar
• Marra F, Bertolani C, Ibrahim MA, et al. Adipokines in liver diseases. Gastroenterology. 2009;92:957–969.
   Google Scholar
• Mosca A, Nobili V, De Vito R, et al. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. J Hepatol. 2017;66:1031–1036.
   PubMed Web of Science ®Google Scholar
• Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877–1887.
   PubMed Web of Science ®Google Scholar
• Takahashi Y. The role of growth hormone and insulin-like growth factor-I in the liver. Int J Mol Sci. 2017;18(7). DOI:10.3390/ijms18071447.
   Web of Science ®Google Scholar
• Ballestri S, Nascimbeni F, Baldelli E, et al. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther. 2017;34:1291–1326.
   PubMed Web of Science ®Google Scholar
• Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014;147:577–594.e1.
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617–649.
   PubMed Web of Science ®Google Scholar
• Giorgio V, Prono F, Graziano F, et al. Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr. 2013;13:40.
   PubMed Web of Science ®Google Scholar
• Vajro P, Lenta S, Pignata C, et al. Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. Ital J Pediatr. 2012;38:55.
   PubMed Web of Science ®Google Scholar
• Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66:180–190.
   PubMed Web of Science ®Google Scholar
• Lee S, Bacha F, Hannon T, et al. Effects of aerobic versus resistance exercise without caloric restriction on abdominal fat, intrahepatic lipid, and insulin sensitivity in obese adolescent boys: a randomized, controlled trial. Diabetes. 2012;61:2787–2795.
   PubMed Web of Science ®Google Scholar
• Ramon-Krauel M, Salsberg SL, Ebbeling CB, et al. A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes. 2013;9:252–260.
   PubMed Web of Science ®Google Scholar
• Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology. 2008;48:119–128.
   PubMed Web of Science ®Google Scholar
• Della Corte C, Vajro P, Socha P, et al. Pediatric non-alcoholic fatty liver disease: recent advances. Clin Res Hepatol Gastroenterol. 2014;38:419–422.
   PubMed Web of Science ®Google Scholar
• Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol. 2017;66:142–152.
   PubMed Web of Science ®Google Scholar
• Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr. 2007;86:285–300.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Butryn ML, Wilson C. Lifestyle modification for the management of obesity. Gastroenterology. 2007;132:2226–2238.
   PubMed Web of Science ®Google Scholar
• Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–129.
   PubMed Web of Science ®Google Scholar
• Koot BGP, van der Baan-Slootweg OH, Clj T-S, et al. Lifestyle intervention for non-alcoholic fatty liver disease: prospective cohort study of its efficacy and factors related to improvement. Arch Dis Child. 2011;96:669–674.
   PubMed Web of Science ®Google Scholar
• Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4:639–644.
   PubMed Web of Science ®Google Scholar
• Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103–107.
   PubMed Web of Science ®Google Scholar
• Kugelmas M, Hill DB, Vivian B, et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38:413–419.
   PubMed Web of Science ®Google Scholar
• Barlow SE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120(Suppl):S164–92.
   PubMed Web of Science ®Google Scholar
• Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. Jama. 2014;311:74–86.
   PubMed Web of Science ®Google Scholar
• Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–752.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Fecht W, Brunt EM, et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology. 2009;49:80–86.
   PubMed Web of Science ®Google Scholar
• Lj B, Jacoby P, Wc SP-D, et al. Low serum 25-hydroxyvitamin D concentrations associate with non-alcoholic fatty liver disease in adolescents independent of adiposity. J Gastroenterol Hepatol. 2014;29:1215–1222.
   PubMed Web of Science ®Google Scholar
• Kwan TK, Chadban SJ, McKenzie PR, et al. Acute oxalate nephropathy secondary to orlistat-induced enteric hyperoxaluria. Nephrol (Carlton) Aust. 2013;18(3):241–242.
   PubMed Web of Science ®Google Scholar
• Mitchel EB, Lavine JE. Review article: the management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40:1155–1170.
   PubMed Web of Science ®Google Scholar
• Manco M, Mosca A, De Peppo F, et al. The benefit of sleeve gastrectomy in obese adolescents on nonalcoholic steatohepatitis and hepatic fibrosis. J Pediatr. 2017;180:31–37.e2.
   PubMed Web of Science ®Google Scholar
• Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;22:18–23.
   Google Scholar
• Shields WW, Thompson KE, Grice GA, et al. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol. 2009;2:157–163.
   PubMedGoogle Scholar
• Omer Z, Cetinkalp S, Akyildiz M, et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2010;22:18–23.
   PubMed Web of Science ®Google Scholar
• Idilman R, Mizrak D, Corapcioglu D, et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008;28:200–208.
   PubMed Web of Science ®Google Scholar
• Garinis GA, Fruci B, Mazza A, et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond). 2010;34:1255–1264.
   PubMed Web of Science ®Google Scholar
• Rakoski MO, Singal AG, Rogers MAM, et al. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2010;32:1211–1221.
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Middleton MS, Deutsch R, et al. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005;21:871–879.
   PubMed Web of Science ®Google Scholar
• Nadeau KJ, Ehlers LB, Zeitler PS, et al. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes. 2009;10:5–13.
   PubMed Web of Science ®Google Scholar
• Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. Jama. 2011;305:1659–1668.
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the diabetes prevention program randomized trial. Ann Intern Med. 2005;142:611–619.
   PubMed Web of Science ®Google Scholar
• Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014;20:573–591.
   PubMed Web of Science ®Google Scholar
• Chao L, Marcus-Samuels B, Mason MM, et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest. 2000;106:1221–1228.
   PubMed Web of Science ®Google Scholar
• Domenici FA, Brochado MJF, Martinelli ADLC, et al. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients. Gene. 2013;529:326–331.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med United States. 2010;362:1675–1685.
   PubMed Web of Science ®Google Scholar
• Singh S, Khera R, Allen AM, et al. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology. 2015;62:1417–1432.
   PubMed Web of Science ®Google Scholar
• Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165:305–315.
   PubMed Web of Science ®Google Scholar
• Sawangjit R, Chongmelaxme B, Phisalprapa P, et al. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore). 2016;95:e4529.
   PubMed Web of Science ®Google Scholar
• Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. Bmj. 2011;342:d1309.
   PubMed Web of Science ®Google Scholar
• Lombardi R, Onali S, Thorburn D, et al. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011640.
   PubMed Web of Science ®Google Scholar
• Cali AMG, Pierpont BM, Taksali SE, et al. Rosiglitazone improves glucose metabolism in obese adolescents with impaired glucose tolerance: a pilot study. Obesity (Silver Spring). 2011;19:94–99.
   PubMed Web of Science ®Google Scholar
• Yau H, Rivera K, Lomonaco R, et al. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep. 2013;13:329–341.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet (London, England). 2016;387:679–690.
   PubMed Web of Science ®Google Scholar
• Nobili V, Manco M, Devito R, et al. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24:1553–1561.
   PubMed Web of Science ®Google Scholar
• Wang C-L, Liang L, Fu J-F, et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol. 2008;14:1598–1602.
   PubMed Web of Science ®Google Scholar
• Zohrer E, Anna A, Jahnel J, et al. Efficacy of docosahexaenoic acid-choline-vitamin E (DHA-CHO-VE) in paediatric NASH: a randomized controlled clinical trial. Appl Physiol Nutr Metab. 2017. [Epub ahead of print]. DOI:10.1139/apnm-2016-0689
   PubMed Web of Science ®Google Scholar
• Lu SC. Regulation of glutathione synthesis. Mol Aspects Med. 2009;30:42–59.
   PubMed Web of Science ®Google Scholar
• Dohil R, Meyer L, Schmeltzer S, et al. The effect of cysteamine bitartrate on adiponectin multimerization in non-alcoholic fatty liver disease and healthy subjects. J Pediatr. 2012;161:639–45.e1.
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Lavine JE, Wilson LA, et al. In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores. Gastroenterology. 2016;151:1141–1154.e9.
   PubMed Web of Science ®Google Scholar
• Contopoulos-Ioannidis DG, Seto I, Hamm MP, et al. Empirical evaluation of age groups and age-subgroup analyses in pediatric randomized trials and pediatric meta-analyses. Pediatrics. 2012;129(Suppl):S161–84.
   PubMed Web of Science ®Google Scholar
• Pathil A, Mueller J, Warth A, et al. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology. 2012;55:1369–1378.
   PubMed Web of Science ®Google Scholar
• Leuschner UFH, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52:472–479.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39:770–778.
   PubMed Web of Science ®Google Scholar
• Vajro P, Franzese A, Valerio G, et al. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr. 2000;136:739–743.
   PubMed Web of Science ®Google Scholar
• Ratziu V, De Ledinghen V, Oberti F, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011;54:1011–1019.
   PubMed Web of Science ®Google Scholar
• Nair S, Cope K, Risby TH, et al. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:1200–1204.
   PubMed Web of Science ®Google Scholar
• Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol. 2003;38:681–687.
   PubMed Web of Science ®Google Scholar
• Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr. 2008;138:1452–1455.
   PubMed Web of Science ®Google Scholar
• Pappo I, Becovier H, Berry EM, et al. Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat. J Surg Res. 1991;51:106–112.
   PubMed Web of Science ®Google Scholar
• Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass–prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology. 1982;82:535–548.
   PubMed Web of Science ®Google Scholar
• Compare D, Coccoli P, Rocco A, et al. Gut–liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2012;22:471–476.
   PubMed Web of Science ®Google Scholar
• Abu-Shanab A, Quigley EMM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol England. 2010;691–701.
   PubMed Web of Science ®Google Scholar
• Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276–1285.
   PubMed Web of Science ®Google Scholar
• Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011;52:740–743.
   PubMed Web of Science ®Google Scholar
• Ma -Y-Y, Li L, Yu C-H, et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013;19:6911–6918.
   PubMed Web of Science ®Google Scholar
• Famouri F, Shariat Z, Hashemipour M, et al. Effects of probiotics on non-alcoholic fatty liver disease in obese children and adolescents: a randomized clinical trial. J Pediatr Gastroenterol Nutr. 2017;64(3):413–417.
   PubMed Web of Science ®Google Scholar
• Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125:1401–1412.
   PubMed Web of Science ®Google Scholar
• Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50:2374–2383.
   PubMed Web of Science ®Google Scholar
• Lambert JE, Parnell JA, Eksteen B, et al. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol. 2015;15:169.
   PubMed Web of Science ®Google Scholar
• Africa JA, Newton KP, Schwimmer JB. Lifestyle interventions including nutrition, exercise, and supplements for nonalcoholic fatty liver disease in children. Dig Dis Sci. 2016;61:1375–1386.
   PubMed Web of Science ®Google Scholar
• Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child. 2011;96:350–353.
   PubMed Web of Science ®Google Scholar
• Nobili V, Alisi A, Della Corte C, et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis. 2013;23:1066–1070.
   PubMed Web of Science ®Google Scholar
• Pacifico L, Bonci E, Di Martino M, et al. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2015;25:734–741.
   PubMed Web of Science ®Google Scholar
• Della Corte C, Carpino G, De Vito R, et al. Docosahexanoic acid plus vitamin D treatment improves features of NAFLD in children with serum vitamin D deficiency: results from a single centre trial. PLoS One. 2016;11:e0168216.
   PubMed Web of Science ®Google Scholar
• Janczyk W, Lebensztejn D, Wierzbicka-Rucinska A, et al. Omega-3 Fatty acids therapy in children with nonalcoholic fatty liver disease: a randomized controlled trial. J Pediatr. 2015;166:1353–1358.
   Web of Science ®Google Scholar
• Du J, Ma -Y-Y, Yu C-H, et al. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2014;20:569–577.
   PubMed Web of Science ®Google Scholar
• Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011;54:1610–1619.
   PubMed Web of Science ®Google Scholar
• Van Wagner LB, Koppe SWP, Brunt EM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011;10:277–286.
   PubMed Web of Science ®Google Scholar
• Giguere V, Yang N, Segui P, et al. Identification of a new class of steroid hormone receptors. Nature. 1988;331:91–94.
   PubMed Web of Science ®Google Scholar
• Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995;81:687–693.
   PubMed Web of Science ®Google Scholar
• Kassam A, Miao B, Young PR, et al. Retinoid X receptor (RXR) agonist-induced antagonism of farnesoid X receptor (FXR) activity due to absence of coactivator recruitment and decreased DNA binding. J Biol Chem. 2003;278:10028–10032.
   PubMed Web of Science ®Google Scholar
• Laffitte BA, Kast HR, Nguyen CM, et al. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem. 2000;275:10638–10647.
   PubMed Web of Science ®Google Scholar
• Wang Y-D, Chen W-D, Moore DD, et al. FXR: a metabolic regulator and cell protector. Cell Res. 2008;18:1087–1095.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004;113:1408–1418.
   PubMed Web of Science ®Google Scholar
• Bjursell M, Wedin M, Admyre T, et al. Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One. 2013;8:e64721.
   PubMed Web of Science ®Google Scholar
• Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006;116:1102–1109.
   PubMed Web of Science ®Google Scholar
• Kong B, Jp L, Tawfik O, et al. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther. 2009;328:116–122.
   PubMed Web of Science ®Google Scholar
• Yang Z-X, Shen W, Sun H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol Int. 2010;4:741–748.
   PubMed Web of Science ®Google Scholar
• Chiang JYL. Bile acid metabolism and signaling. Compr Physiol. 2013;3:1191–1212.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet (London, England). 2015;385:956–965.
   PubMed Web of Science ®Google Scholar
• Makri E, Cholongitas E, Tziomalos K. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. World J Gastroenterol United States. 2016; 22(41):9039–9043.
   PubMed Web of Science ®Google Scholar
• Li L, Chen L, Hu L, et al. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology. 2011;54:1620–1630.
   PubMed Web of Science ®Google Scholar
• Do JE, Kwon SY, Park S, et al. Effects of vitamin D on expression of Toll-like receptors of monocytes from patients with Behcet’s disease. Rheumatology (Oxford). 2008;47:840–848.
   PubMed Web of Science ®Google Scholar
• Miura K, Seki E, Ohnishi H, et al. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2010;2010:362847.
   PubMed Web of Science ®Google Scholar
• Sadeghi K, Wessner B, Laggner U, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol. 2006;36:361–370.
   PubMed Web of Science ®Google Scholar
• Dickie LJ, Church LD, Coulthard LR, et al. Vitamin D3 down-regulates intracellular toll-like receptor 9 expression and toll-like receptor 9-induced IL-6 production in human monocytes. Rheumatology (Oxford). 2010;49:1466–1471.
   PubMed Web of Science ®Google Scholar
• Murillo G, Nagpal V, Tiwari N, et al. Actions of vitamin D are mediated by the TLR4 pathway in inflammation-induced colon cancer. J Steroid Biochem Mol Biol. 2010;121:403–407.
   PubMed Web of Science ®Google Scholar
• Rivera CA, Adegboyega P, Van Rooijen N, et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007;47:571–579.
   PubMed Web of Science ®Google Scholar
• Braunersreuther V, Viviani GL, Mach F, et al. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol. 2012;18:727–735.
   PubMed Web of Science ®Google Scholar
• Miura K, Kodama Y, Inokuchi S, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 2010;139:323–34.e7.
   PubMed Web of Science ®Google Scholar
• Miura K, Yang L, Van Rooijen N, et al. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology. 2013;57:577–589.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577–1586.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Reyes MJ, Mishra A, et al. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther. 2014;39:3–14.
   PubMed Web of Science ®Google Scholar
• Li J, Song J, Zaytseva YY, et al. An obligatory role for neurotensin in high-fat-diet-induced obesity. Nature. 2016;533:411–415.
   PubMed Web of Science ®Google Scholar